Monoclonal anti-insulin-like growth fact

Not available outside of the UK & Ireland.

Application

Anti- Insulin-Like Growth Factor Binding Protein-1 antibody may be used for immunoblotting at a working concentration of 1-2 µg/ml. For ELISA, a working concentration of 2 µg/ml may be used. The antibody is suitable for neutralization reactions (ND50 is 10-40 µg/ml).

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

The effects of insulin-like growth factors (IGF) are modulated by a family of insulin-like growth factor binding proteins 1-6. (IGFBPs -1-6). IGFBP-1 is secreted as an endocrine factor by liver, kidneys, decidua and in human amniotic fluid, but has the ability to signal in autocrine and paracrine fashion. Post-translational modifications such as ubiquitination, glycosylation and phosphorylation alter the activity of IGFBPs. Phosphorylation of IGFBP-1 is mainly mediated by Casein kinase I and II and cAMP-dependent protein kinases. IGFBP-1 alters the bioavailability of IGF in the serum by binding and sequestration so that a regulated amount id available to act on the target cells. The functions of IGFBP-1 are most important in the physiology of female reproductive system in mammals, for growth and development of the developing fetus Monoclonal Anti-Human Insulin-like Growth Factor Binding Protein-1 (IGFBP-1) recognizes recombinant human IGFBP-1. No cross-reactivity is seen with recombinant human IGFBP-2, IGFBP-3, and IGFBP-4.

Immunogen

purified recombinant human insulin-like growth factor binding protein 1, expressed in E. coli.

Physical form

Lyophilized from a 0.2 µm filtered solution in phosphate buffered saline.

Specificity

The biological activity is measured by its ability to neutralize recombinant human IGFBP-1 in the presence of recombinant human IGF-I.